Vicore Pharma Holding AB (publ) (VICO.ST)

Compare

6.80

-0.14

(-2.02%)

At close: April 4 at 5:29:50 PM GMT+2

Vicore to Participate in the Van Lanschot Kempen Life Sciences Conference

STOCKHOLM, SE / ACCESS Newswire / March 28, 2025 /Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, ...

ACCESS Newswire 9 days ago

VICO.ST
-2.02%
Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

STOCKHOLM, SE / ACCESS Newswire / March 26, 2025 / Vicore Pharma Holding (STO:VICO) The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804 ("Vicore Pharma" or the "company"), with its registered offices in Stockholm, are summoned ...

ACCESS Newswire 11 days ago

VICO.ST
-2.02%
Vicore Publishes the Annual Report for 2024

STOCKHOLM, SE / ACCESS Newswire / March 26, 2025 /Vicore Pharma Holding (STO:VICO) Stockholm, March 26, 2025 - Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), ...

ACCESS Newswire 11 days ago

VICO.ST
-2.02%
Vicore Pharma Holding Year-End Report 2024

STOCKHOLM, SWEDEN / ACCESS Newswire / February 27, 2025 / Vicore Pharma Holding (STO:VICO) Stockholm, February 27, 2025 - Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor ...

ACCESS Newswire last month

VICO.ST
-2.02%
Vicore to Present at Upcoming Investor Conferences

STOCKHOLM, SWEDEN / ACCESS Newswire / February 26, 2025 / Vicore Pharma Holding (STO:VICO) Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation ...

ACCESS Newswire last month

VICO.ST
-2.02%
Increase of Number of Shares and Votes in Vicore Pharma

STOCKHOLM, SE / ACCESSWIRE / May 31, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 31, 2024 - Vicore Pharma Holding AB (STO: VICO) ("Vicore") announced today that the number of Vicore shares and votes has increased following the exercise ...

ACCESS Newswire 10 months ago

VICO.ST
-2.02%
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis

STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 / Vicore Pharma Holding (STO:VICO) Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment. The therapy was safe and well tolerated with no treatment-related ...

ACCESS Newswire 10 months ago

VICO.ST
-2.02%
Vicore Expands and Strengthens its Board of Directors

STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin ...

ACCESS Newswire 10 months ago

VICO.ST
-2.02%
Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

STOCKHOLM, SE / ACCESSWIRE / May 7, 2024 / Vicore Pharma Holding (STO:VICO) The following resolutions were passed at the annual general meeting (the "AGM") of Vicore Pharma Holding AB (publ) on 7 May 2024. Adoption of income statement and balance ...

ACCESS Newswire 10 months ago

VICO.ST
-2.02%
Interim Report January-March 2024

STOCKHOLM, SWEDEN / ACCESSWIRE / May 3, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists ...

ACCESS Newswire 10 months ago

VICO.ST
-2.02%

Performance Overview

Return	VICO.ST	OMX Stockholm 30 Index (^OMX)
YTD	-19.53%	-7.89%
1-Year	-61.88%	-9.30%
3-Year	-70.31%	+7.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vicore Pharma Holding AB (publ) (VICO.ST)

Vicore to Participate in the Van Lanschot Kempen Life Sciences Conference

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

Vicore Publishes the Annual Report for 2024

Vicore Pharma Holding Year-End Report 2024

Vicore to Present at Upcoming Investor Conferences

Increase of Number of Shares and Votes in Vicore Pharma

Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis

Vicore Expands and Strengthens its Board of Directors

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

Interim Report January-March 2024

Performance Overview